Skip to content
MedsAcross

Molecule

Sodium thiosulfate

Available on requestOrphanAntidotes
Presentations
2
Brands
1
Manufacturers
1
Available from stock
0

Sodium thiosulfate is a prescription medicine indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. It is available as injection for intravenous use. MedsAcross supplies Sodium thiosulfate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

ATC classification
V03AB06 Sodium thiosulfate · Antidote
US FDA first approval
14 February 1992
EU status
Authorised
Orphan designation
Yes
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Intravenous
Dosage forms
Injection
Identifiers
UNII L0IYT1O31NRxCUI 1807514CAS 7772-98-7Q339866

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Sodium Thiosulfate Injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. When the diagnosis of cyanide poisoning is uncertain, the potential risks associated with Sodium Thiosulfate Injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis. Sodium Thiosulfate Injection, an antidote, is indicated for sequential use with sodium nitrite for treatment of acute cyanide poisoning that is judged to be serious or life-threatening. Use with caution if the diagnosis of cyanide poisoning is uncertain.

Source: US FDA prescribing information

How it works

Exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular hypoxia and metabolic acidosis. In massive acute cyanide poisoning, the mechanism of toxicity may involve other enzyme systems as well. The synergy resulting from treatment of cyanide poisoning with the combination of sodium nitrite and sodium thiosulfate is the result of differences in their primary mechanisms of action as antidotes for cyanide poisoning.

Source: US FDA prescribing information

Dosing overview

2. DOSAGE AND ADMINISTRATION If clinical suspicion of cyanide poisoning is high, administer Sodium Thiosulfate Injection without delay and in conjunction with appropriate airway, ventilatory, and circulatory support. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. Dosing: Age Intravenous Dose of Sodium Nitrite and Sodium Thiosulfate Adults 1.) Sodium Nitrite -10 mL of sodium nitrite at the rate of 2.5 to 5 mL/minute 2.) Sodium Thiosulfate - 50 mL of sodium thiosulfate immediately following administration of sodium nitrite.

Source: US FDA prescribing information

Warnings and precautions

Sulfites: Sodium thiosulfate may contain trace impurities of sodium sulfite Sulfites Sodium thiosulfate drug product may contain trace impurities of sodium sulfite. The presence of a trace amount of sulfites in this product should not deter administration of the drug for treatment of emergency situations, even if the patient is sulfite-sensitive.

Source: US FDA prescribing information

Side effects

There have been no controlled clinical trials conducted to systematically assess the adverse events profile of sodium thiosulfate. The medical literature has reported the following adverse events in association with sodium thiosulfate administration. These adverse events were not reported in the context of controlled trials or with consistent monitoring and reporting methodologies for adverse events. Therefore, frequency of occurrence of these adverse events cannot be assessed.

Source: US FDA prescribing information

Storage

Store at controlled room temperature between 20°C and 25°C (68°F to 77°F), excursions permitted from 15 to 30°C (59 to 86°F). Do not freeze. (Note: Sodium Nitrite must be obtained separately.) Protect from direct light.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

2 presentations of Sodium thiosulfate, sorted by availability.

MedicineManufacturerRegisterAvailability
Pedmark 12.5 g/100 mL injectionIntravenousFennec PharmaceuticalsUS FDAAvailable on request
Sodium thiosulfate 12500 mg/50 mL injectionIntravenousGeneric name—US FDAAvailable on request

Brands by market

1 brand names across 1 markets.

Brand names by country

United States

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 14 February 1992Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Sodium thiosulfate in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Sodium thiosulfate available for export from India?

Yes, on request. MedsAcross lists 2 presentations of Sodium thiosulfate and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Sodium thiosulfate have?

The catalogue lists 1 brand names for Sodium thiosulfate, including Pedmark.

Is Sodium thiosulfate approved by the US FDA?

Yes. The US FDA first approved Sodium thiosulfate on 14 February 1992, according to Drugs@FDA.

Is Sodium thiosulfate authorised in the European Union?

Yes. Sodium thiosulfate has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.

Does Sodium thiosulfate need cold chain shipping?

No listed presentation of Sodium thiosulfate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Sodium thiosulfate in?

Sodium thiosulfate is classified under ATC code V03AB06 (Sodium thiosulfate).

References

  1. Sodium Thiosulfate prescribing information (Hope Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 26 May 2026
  2. Pedmarqsi: European public assessment report (EPAR). European Medicines Agency. Retrieved 23 May 2025

Request Sodium thiosulfate for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.